All the Drug Class Drugs
Anticoagulant, Direct Factor Xa Inhibitor. Apixaban 2.5 mg, Apixaban 5 mg. FC tabs 2.5mg/5 mg X30
Prevent. of VTE (VTEp): elect. hip or knee replacem. surgery 2.5 mg taken orally 2Xd, initial dose to be taken 12 to 24 hs after surg. In ptts. undergoing hip replacem., tmt. is 32 to 38 days. In ptts. undergoing knee replacem., tmt. is 10 to 14 days. Prevent. of stroke and syst. embol. in ptts. with non-valv. atrial fibrill. (NVAF): 5 mg taken orally 2Xd. See full prescript. info.
for 2.5 mg: prevent. of venous thromboemb. events (VTE) in adlt. ptts. who have undergone elect. hip or knee replacem.
for both 2.5 and 5 mg: prevent. of stroke and syst. embol. in adlt. ptts. with non-valv. atrial fibrill. (NVAF), with one or more risk factors, such as prior stroke or transient isch. attack (TIA); age≥ 75 y; HT; diabetes mellitus; sympt. heart fail. (NYHA Class ≥ II). Tmt. of deep vein thromb.(DVT) and pulmon. embol. (PE), and prevent. of recurrent DVT and PE in adults.
C/I: Hypersens. Act. clin. signif. bleeding. • Hep. dis. assoc. with coagulopathy and clinic. relevant bleeding risk • Lesion or condit. posing a signif. risk factor for major bleeding, incl. current or recent GI ulcerat., presence of malign. neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surg., recent intracran. haemorrhage, known or susp. oesophageal varices, arteriovenous malform., vasc. aneurysms or major intraspinal or intracerebral vasc. abnorm. • Concom. tmt. with any other anticoag. agent e.g. unfraction. heparin (UFH), low MW heparins (enoxaparin, dalteparin, etc.), heparin deriv. (fondaparinux, etc.), oral anticoag. (warfarin, rivaroxaban, dabigatran, etc.) except under spec. circumst. of switching anticoag. ther. or when UFH is given at doses necess. to maintain an open ctral. venous or arterial catheter.
Anticoagulant. Warfarin (sodium) 1, 2, 2.5, 5 mg. TABS: 30 x 1 mg, 2 mg,
2.5 mg, 5 mg. See lit.
Proph.and/or tmt. ven. thromb. (and its
extension), pulm. embolism, proph. and/
or
tmt. thromb. embol. complicats. assoc.
with atrial fibrill. and/or card. valve
replace., reduce risk death, recur. M.I.,
stroke, system. embol. aft. M.I.
C/I: Hypersens., pregn., hemorrh., bleed.
tendencies, blood dyscras., recent/
complic. surg., threat. abort., eclamps.,
pre-eclamps.
Anticoagulant, Direct Factor Xa Inhibitor. Apixaban 2.5 mg, 5 mg. Preven. of VTE (VTEp): elective hip or
knee replac. surg.- 2.5 mg ×2/d.
Init. dose should be taken 12 - 24 hrs.
after surg.
In pts. underg. hip replac. surg.- The
recom. duration of tmt. is 32- 38 d.
In pts. underg. knee replac. surg.: The
recom. duration of tmt. is 10- 14 d.
Preven. of stroke & syst. embol. in pts.
with non-valvul. atrial fibril. (NVAF):
5 mg ×2/d.
Dose reduction: 2.5mg×2/d in pts. with
NVAF and at least two of the follow.
characteristics: age ≥ 80 yrs., bdy. wt. ≤
60 kg, or ser. Cr ≥ 1.5 mg/dL (133
micromole/L).
Ther. should be cont. long term.
Tmt. of DVT, tmt. of PE and preven. of
recur. DVT &PE (VTEt)
Tmt. of acute DVT and tmt. of PE is 10
mg×2/d for the first 7 d. follow. by 5
mg ×2/d.
As per avail. med. guidelines, short
durat. of tmt. (at least 3 mnths.) should
be based on transient risk factor. (e.g.
recent surg., trauma, immobilis.).
Preven. of recur. DVT & PE is 2.5
mg×2/d. When preven. of recur. DVT &
PE is indic., the 2.5 mg×2/d should be
init. follow. complet. of 6 mnths. of tmt.
5 mg×2/d or with another anticoag.
See Lit.
2.5 mg tabs. - Preven. of VTE in adult pts.
who have undergone elect. hip or knee
replac. surg.
Preven. of stroke and syst. embol. in adult
pts. NVAF, with one/ more risk fact., e.g as
prior stroke, TIA; age ≥ 75 yrs.; hypertens.;
diabetes. mell.; symptom. HF (NYHA Class
≥ II).
Tmt. of DVT, PE , and preven. of recur.
DVT & PE in adult.
5 mg tabs. - Preven. of stroke, syst. embol.
in adult pts. NVAF, with one/ more risk
fact., e.g. prior stroke or TIA; age ≥ 75 yrs.;
hypertens.; diabetes mell.; symptom. HF
(NYHA Class ≥ II).
Tmt. of DVT, PE in adult.
C/I: Hypersens.
Active clinic. signific. bleed.
Hep. dis. assoc. with coagulopathy
&clinic. relevant bleed. risk.
Lesion/ condit. if consid. a signific. risk
factor for major bleed. This may include
current or recent GI ulcer., presence of
malig. neoplasm. at high risk of bleed.,
recent brain, spinal inj., recent brain,
spinal or ophthalmic surg., recent
intracran. haemorrhage, known/
suspect. esophagi. varices, arterioven.
malform., vasc. aneurysms or major
intraspinal or intracerebr. vascular
abnorm.
Concom. tmt. with any other anticoag.
agent e.g. unfraction. heparin (UHF), low
molec. wt. heparins (enoxaparin,
dalteparin, etc.), heparin derivat.
(fondaparinux, etc.), oral anticoag.
(warfarin, rivaroxaban, dabigatran, etc.)
except under specific circumstances of
switching anticoag. ther.or when UHF is
given at doses necessary to maintain an
open centr. ven. or arterial catheter or when UFH is given during catheter ablation for atrial fibrillation
Anticoagulant. Heparin 25,000 IU / 5 ml. VIALS: 25 x 5 ml. I.V./S.C.
See lit.
Thrombo-embol. disords., proph. deep
vein thromb., thrombo-embol. events.
Anticoagulant. Heparin Sodium 5000 IU/ml. Sol. for inj.: 5 ml vials with 5000 IU/ml See lit..
Prevent. of thromboembolic dis.
Part of tmt of venous or arter. thromboemb. dis.
For anticoag. during tmt or operat. with extracorporeal circ.
C/I:Hypersens. Ac. or prev. hist. of heparin-induc. allergic thrombocytopenia (type 2). Dis. assoc. with a bleeding diathesis, severe hepatic, renal or pancr. dis.
Dis. with susp. lesion of the vasc. system, e.g. GI ulcers, hypertension (>105 mmHg diastolic), cerebral haemorrhage, trauma or surgery involving the CNS, eye operat., retinopathies, vitreous haemorrhage, aneurysm of the cerebral arteries, infect. endocard. Threatened miscarriage. Spinal anaesth, epidural anaesth, lumbar punct.
Organ lesions assoc. with bleeding tendency.
Must not be used in preterm or newborn babies because of benzyl alcohol content.
Anticoagulant. Heparin Sodium 25000 IU / 5 ml. VIAL (Sol. for inj./infus.): 1×25000IU/5ml.
Dosage must be individ. adjust.
Prevent. of thromboembol. disord. As part of the tmt. of ven. and arter. thromboembol. disord. (includ. early tmt. of heart attacks as well as unst. angina. pect.). For the anticoagulant. in case of tmt. or operation with extracorporeal circul. (e.g.heart-lung machine, hemodialysis).
C/I: Hypersens. Current/ prev. hist. of heparin-induced allergic thrombocytop. (type 2). Disorders assoc. with a bleed. diathesis, e.g. thrombocytop., coagulopathies, sev. hep./renal/pancreat. disord. Disord. in which there is a suspect. lesion of the vascul. syst., e.g. GI ulc., hypertens. (>105 mm Hg diastolic), cereb. haemorrhage, traum. or surg. operat. involve. the CNS, eye operat., retinopathies, vitreous haemorrhage, aneurysm of the cereb. arteries, infect. endocarditis. Threatened miscarriage - Spinal anaesthesia, epid. anaesthesia, lumb. punct. - Organ lesions assoc. with a bleed. tendency. Use in preterm/newborns dueto benzyl alcohol content.
